O	0	5	SOLTI
O	6	13	NeoPARP
O	13	14	:
O	15	16	a
O	17	22	phase
O	23	25	II
O	26	36	randomized
O	37	42	study
O	43	45	of
O	46	49	two
O	50	59	schedules
O	60	62	of
B-intervention	63	71	iniparib
I-intervention	72	76	plus
I-intervention	77	87	paclitaxel
O	88	94	versus
B-control	95	105	paclitaxel
I-control	106	111	alone
O	112	114	as
O	115	126	neoadjuvant
O	127	134	therapy
O	135	137	in
O	138	146	patients
O	147	151	with
O	152	158	triple
O	158	159	-
O	159	167	negative
O	168	174	breast
O	175	181	cancer
O	181	182	.

O	183	191	Iniparib
O	192	194	is
O	195	197	an
O	198	213	investigational
O	214	219	agent
O	220	224	with
O	225	234	antitumor
O	235	243	activity
O	244	246	of
O	247	260	controversial
O	261	270	mechanism
O	271	273	of
O	274	280	action
O	280	281	.

O	282	285	Two
O	286	294	previous
O	295	301	trials
O	302	304	in
O	305	313	advanced
O	314	320	triple
O	320	321	-
O	321	329	negative
O	330	336	breast
O	337	343	cancer
O	344	345	(
O	345	349	TNBC
O	349	350	)
O	351	353	in
O	354	365	combination
O	366	370	with
O	371	382	gemcitabine
O	383	386	and
O	387	398	carboplatin
O	399	405	showed
O	406	410	some
O	411	419	evidence
O	420	422	of
O	423	431	efficacy
O	432	436	that
O	437	440	was
O	441	444	not
O	445	454	confirmed
O	454	455	.

O	456	460	This
O	461	466	phase
O	467	469	II
O	470	480	randomized
O	481	492	neoadjuvant
O	493	498	study
O	499	502	was
O	503	511	designed
O	512	514	to
O	515	522	explore
O	523	526	its
O	527	535	activity
O	536	539	and
O	540	552	tolerability
O	553	557	with
O	558	564	weekly
O	565	575	paclitaxel
O	576	577	(
O	577	580	PTX
O	580	581	)
O	582	584	as
O	585	596	neoadjuvant
O	597	606	treatment
O	607	609	in
O	610	614	TNBC
O	615	623	patients
O	623	624	.

B-total-participants	625	628	141
B-eligibility	629	637	patients
I-eligibility	638	642	with
I-eligibility	643	648	Stage
I-eligibility	649	651	II
I-eligibility	651	652	-
I-eligibility	652	656	IIIA
I-eligibility	657	661	TNBC
O	662	666	were
O	667	675	randomly
O	676	684	assigned
O	685	687	to
O	688	695	receive
B-control	696	699	PTX
O	700	701	(
O	701	703	80
O	704	706	mg
O	706	707	/
O	707	708	m
O	708	709	(
O	709	710	2
O	710	711	)
O	711	712	,
O	713	715	d1
O	715	716	;
O	717	718	n
O	719	720	=
B-control-participants	721	723	47
O	723	724	)
O	725	730	alone
O	731	733	or
O	734	736	in
O	737	748	combination
O	749	753	with
O	754	762	iniparib
O	762	763	,
O	764	770	either
O	771	775	once
O	775	776	-
O	776	782	weekly
O	783	784	(
O	784	787	PWI
O	787	788	)
O	789	790	(
O	790	792	11
O	792	793	.
O	793	794	2
O	795	797	mg
O	797	798	/
O	798	800	kg
O	800	801	,
O	802	804	d1
O	804	805	;
O	806	807	n
O	808	809	=
B-intervention-participants	810	812	46
O	812	813	)
O	814	816	or
O	817	822	twice
O	822	823	-
O	823	829	weekly
O	830	831	(
O	831	834	PTI
O	834	835	)
O	836	837	(
O	837	838	5
O	838	839	.
O	839	840	6
O	841	843	mg
O	843	844	/
O	844	846	kg
O	846	847	,
O	848	850	d1
O	850	851	,
O	852	853	4
O	853	854	;
O	855	856	n
O	857	858	=
B-intervention-participants	859	861	48
O	861	862	)
O	863	866	for
O	867	869	12
O	870	875	weeks
O	875	876	.

O	877	884	Primary
O	885	893	endpoint
O	894	897	was
B-outcome-Measure	898	908	pathologic
I-outcome-Measure	909	917	complete
I-outcome-Measure	918	926	response
I-outcome-Measure	927	928	(
I-outcome-Measure	928	931	pCR
I-outcome-Measure	931	932	)
I-outcome-Measure	933	935	in
I-outcome-Measure	936	939	the
I-outcome-Measure	940	946	breast
O	946	947	.

B-outcome	948	951	pCR
I-outcome	952	956	rate
O	957	960	was
O	961	968	similar
O	969	974	among
O	975	978	the
O	979	984	three
O	985	989	arms
O	990	991	(
B-cv-bin-percent	991	993	21
O	993	994	,
B-iv-bin-percent	995	997	22
O	997	998	,
O	999	1002	and
B-iv-bin-percent	1003	1005	19
I-iv-bin-percent	1006	1007	%
O	1008	1011	for
O	1012	1015	PTX
O	1015	1016	,
O	1017	1020	PWI
O	1020	1021	,
O	1022	1025	and
O	1026	1029	PTI
O	1029	1030	,
O	1031	1043	respectively
O	1043	1044	)
O	1044	1045	.

O	1046	1055	Secondary
O	1056	1064	efficacy
O	1065	1074	endpoints
O	1075	1079	were
O	1080	1090	comparable
O	1090	1091	:
B-outcome	1092	1095	pCR
I-outcome	1096	1098	in
I-outcome	1099	1105	breast
I-outcome	1106	1109	and
I-outcome	1110	1116	axilla
O	1117	1118	(
B-cv-bin-percent	1118	1120	21
O	1120	1121	,
B-iv-bin-percent	1122	1124	17
O	1124	1125	,
O	1126	1129	and
B-iv-bin-percent	1130	1132	19
I-iv-bin-percent	1133	1134	%
O	1134	1135	)
O	1135	1136	;
B-outcome	1137	1141	best
I-outcome	1142	1149	overall
I-outcome	1150	1158	response
O	1159	1161	in
O	1162	1165	the
O	1166	1172	breast
O	1173	1174	(
B-cv-bin-percent	1174	1176	60
O	1176	1177	,
B-iv-bin-percent	1178	1180	61
O	1180	1181	,
O	1182	1185	and
B-iv-bin-percent	1186	1188	63
I-iv-bin-percent	1189	1190	%
O	1190	1191	)
O	1191	1192	;
O	1193	1196	and
B-outcome	1197	1203	breast
I-outcome	1204	1216	conservation
I-outcome	1217	1221	rate
O	1222	1223	(
B-cv-bin-percent	1223	1225	53
O	1225	1226	,
B-iv-bin-percent	1227	1229	54
O	1229	1230	,
O	1231	1234	and
B-iv-bin-percent	1235	1237	50
I-iv-bin-percent	1238	1239	%
O	1239	1240	)
O	1240	1241	.

O	1242	1250	Slightly
O	1251	1255	more
O	1256	1264	patients
O	1265	1267	in
O	1268	1271	the
O	1272	1275	PTI
O	1276	1279	arm
O	1280	1289	presented
B-outcome	1290	1295	grade
I-outcome	1296	1297	3
I-outcome	1297	1298	/
I-outcome	1298	1299	4
I-outcome	1300	1311	neutropenia
O	1312	1313	(
B-cv-bin-percent	1313	1314	4
O	1314	1315	,
B-iv-bin-percent	1316	1317	0
O	1317	1318	,
O	1319	1322	and
B-iv-bin-percent	1323	1325	10
I-iv-bin-percent	1326	1327	%
O	1327	1328	)
O	1328	1329	.

B-outcome	1330	1335	Grade
I-outcome	1336	1337	1
I-outcome	1337	1338	/
I-outcome	1338	1339	2
O	1340	1341	(
B-cv-bin-percent	1341	1343	28
O	1343	1344	,
B-iv-bin-percent	1345	1347	22
O	1347	1348	,
O	1349	1352	and
B-iv-bin-percent	1353	1355	29
I-iv-bin-percent	1356	1357	%
O	1357	1358	)
O	1358	1359	,
O	1360	1363	but
B-cv-bin-abs	1364	1366	no
B-outcome	1367	1372	grade
I-outcome	1373	1374	3
I-outcome	1374	1375	/
I-outcome	1375	1376	4
I-outcome	1377	1387	neuropathy
O	1387	1388	,
O	1389	1392	was
O	1393	1401	observed
O	1401	1402	.

O	1403	1408	There
O	1409	1413	were
O	1414	1416	no
O	1417	1428	differences
O	1429	1431	in
O	1432	1439	serious
O	1440	1447	adverse
O	1448	1454	events
O	1455	1458	and
O	1459	1468	treatment
O	1468	1469	-
O	1469	1477	emergent
O	1478	1485	adverse
O	1486	1492	events
O	1493	1500	leading
O	1501	1503	to
O	1504	1513	treatment
O	1514	1529	discontinuation
O	1530	1535	among
O	1536	1539	the
O	1540	1545	three
O	1546	1550	arms
O	1550	1551	.

O	1552	1560	Addition
O	1561	1563	of
O	1564	1572	iniparib
O	1573	1575	to
O	1576	1582	weekly
O	1583	1586	PTX
O	1587	1590	did
O	1591	1594	not
O	1595	1598	add
O	1599	1607	relevant
O	1608	1617	antitumor
O	1618	1626	activity
O	1627	1629	or
O	1630	1638	toxicity
O	1638	1639	.

O	1640	1645	These
O	1646	1653	results
O	1654	1656	do
O	1657	1660	not
O	1661	1668	support
O	1669	1676	further
O	1677	1687	evaluation
O	1688	1690	of
O	1691	1694	the
O	1695	1706	combination
O	1707	1709	of
O	1710	1718	iniparib
O	1719	1721	at
O	1722	1727	these
O	1728	1733	doses
O	1734	1738	plus
O	1739	1749	paclitaxel
O	1750	1752	in
O	1753	1758	early
O	1759	1763	TNBC
O	1763	1764	.
